Emerging drugs for the treatment of irritability associated with autism spectrum disorder

References

• Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014 Mar 8;383(9920):896–910. doi: 10.1016/S0140-6736(13)61539-1
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association D, Association AP. Diagnostic and statistical manual of mental disorders: dSM-5 Vol. 5. Washington (DC): American psychiatric association; 2013. p. 5.
   Google Scholar
• Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: A systematic review update. Autism Res. 2022 May;15(5):778–790.
   PubMed Web of Science ®Google Scholar
• Solmi M, Song M, Yon DK, et al. Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. Mol Psychiatry. 2022 Oct;27(10):4172–4180.
   PubMed Web of Science ®Google Scholar
• Weye N, Santomauro DF, Agerbo E, et al. Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. Lancet Psychiatry. 2021 Apr;8(4):310–319.
   PubMed Web of Science ®Google Scholar
• Rogge N, Janssen J. The economic costs of autism spectrum disorder: a literature review. J Autism Dev Disord. 2019 Jul 01;49(7):2873–2900.
   PubMed Web of Science ®Google Scholar
• Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007 Nov;120(5):1162–1182. doi: 10.1542/peds.2007-2362
   PubMed Web of Science ®Google Scholar
• Keluskar J, Reicher D, Gorecki A, et al. Understanding, assessing, and intervening with emotion dysregulation in autism spectrum disorder: a developmental perspective. Child Adolesc Psychiatr Clin N Am. 2021 Apr 01;30(2):335–348. doi: 10.1016/j.chc.2020.10.013
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002 Aug 1;347(5):314–321. doi: 10.1056/NEJMoa013171
   PubMed Web of Science ®Google Scholar
• Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005 Nov;44(11):1137–44.
   PubMed Web of Science ®Google Scholar
• Lamy M, Pedapati EV, Dominick KL, et al. Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents. Pediatr Drugs. 2020 Oct 01;22(5):473–483. doi: 10.1007/s40272-020-00408-0.
   PubMed Web of Science ®Google Scholar
• Farmer C, Thurm A, Grant P. Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs. 2013 Mar;73(4):303–314. doi: 10.1007/s40265-013-0021-7
   PubMed Web of Science ®Google Scholar
• Salazar de Pablo G, Pastor Jordá C, Vaquerizo-Serrano J, et al. Systematic review and meta-analysis: efficacy of pharmacological interventions for irritability and emotional dysregulation in autism spectrum disorder and predictors of response. J Am Acad Child Adolesc Psychiatry. 2023 Feb;62(2):151–168. doi: 10.1016/j.jaac.2022.03.033
   PubMed Web of Science ®Google Scholar
• McPartland J, Volkmar FR. Autism and related disorders. Handb Clin Neurol. 2012;106:407–418.
   PubMedGoogle Scholar
• Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics. 2010 Jul;7(3):283–92. doi: 10.1016/j.nurt.2010.05.003
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S. Repositioning drugs for psychiatry. Avicenna J Med Biotechnol. 2020 Apr;12(2):67.
   PubMedGoogle Scholar
• Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. doi: 10.1186/s41073-019-0064-8
   PubMedGoogle Scholar
• Mohammadi MR, Yadegari N, Hassanzadeh E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin Neuropharmacol. 2013 Nov;36(6):179–84.
   PubMed Web of Science ®Google Scholar
• Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol. 2007 Oct;17(4):434–447. doi: 10.1111/j.1750-3639.2007.00102.x
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Asadabadi M, Mohammadi M-R, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013;16(4):783–789. doi: 10.1017/S1461145712000880
   PubMed Web of Science ®Google Scholar
• Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, et al. Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial? Clin Neuropharmacol. 2020 Sep;43(5):139–145.
   PubMed Web of Science ®Google Scholar
• Mendez MA, Horder J, Myers J, et al. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology. 2013 May;68:195–201.
   PubMed Web of Science ®Google Scholar
• Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016 Feb;137(Suppl 2):S124–S135.
   PubMedGoogle Scholar
• Ghaleiha A, Ghyasvand M, Mohammadi M-R, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2014;28(7):677–685. doi: 10.1177/0269881113508830
   PubMed Web of Science ®Google Scholar
• Posey DJ, Stigler KA, Erickson CA, et al. Antipsychotics in the treatment of autism. J Clin Investig. 2008;118(1):6–14. doi: 10.1172/JCI32483
   PubMed Web of Science ®Google Scholar
• Pavăl D. A dopamine hypothesis of autism spectrum disorder. Dev Neurosci. 2017;39(5):355–360. doi: 10.1159/000478725
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Mikami K, Okada T, et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry Hum Dev. 2017 Oct;48(5):796–806.
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Bruce TO, Ballard JF et al. Poster session III: An Open-Label Trial of Aripiprazole in the Treatment of Autism and Its Correlation to Whole Blood Serotonin Levels and Serotonin Transporter (5HTTPLR) Function. Neuropsychopharmacology. Proceedings of the American College of Neuropsychopharmacology 45th Annual Meeting; 2006 December 3‐7; Hollywood, Florida. 2006;31(Suppl 1s):S259–60.
   Google Scholar
• Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;2016(6):6. doi: 10.1002/14651858.CD009043.pub3
   Google Scholar
• Hafizi S, Tabatabaei D, Lai M-C. Review of clinical studies targeting inflammatory pathways for individuals with autism [review]. Front Psychiatry. 2019 Nov 25;10:10. doi: 10.3389/fpsyt.2019.00849
   PubMed Web of Science ®Google Scholar
• Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacol (Berl). 2013 Jan;225(1):51–59.
   PubMed Web of Science ®Google Scholar
• Blaylock R, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem. 2009;16(2):157–170. doi: 10.2174/092986709787002745
   PubMed Web of Science ®Google Scholar
• Momtazmanesh S, Amirimoghaddam-Yazdi Z, Moghaddam HS, et al. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 2020 Jul;74(7):398–405.
   PubMed Web of Science ®Google Scholar
• Nikoo M, Radnia H, Farokhnia M, et al. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015 Jan;38(1):11–7.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec;124(6):1533–1540.
   PubMed Web of Science ®Google Scholar
• Nikvarz N, Alaghband-Rad J, Tehrani-Doost M, et al. Comparing efficacy and side effects of memantine vs. Risperidone in the treatment of autistic disorder. Pharmacopsychiatry. 2017 Jan;50(1):19–25.
   PubMed Web of Science ®Google Scholar
• Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15550–15555. doi: 10.1073/pnas.1416940111
   PubMed Web of Science ®Google Scholar
• Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder. Mol Autism. 2021 May 25;12(1):38. doi: 10.1186/s13229-021-00447-5
   PubMed Web of Science ®Google Scholar
• Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012 Jun 1;71(11):956–961. doi: 10.1016/j.biopsych.2012.01.014
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013 Jul 25;13(1):196. doi: 10.1186/1471-244X-13-196
   PubMedGoogle Scholar
• Dean OM, Gray KM, Villagonzalo KA, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. 2017 Mar;51(3):241–249.
   PubMed Web of Science ®Google Scholar
• Khalaj M, Saghazadeh A, Shirazi E, et al. Palmitoylethanolamide as adjunctive therapy for autism: efficacy and safety results from a randomized controlled trial. J Psychiatr Res. 2018 Aug;103:104–111.
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):32–36. doi: 10.1016/j.pnpbp.2009.09.012
   PubMed Web of Science ®Google Scholar
• Moazen-Zadeh E, Shirzad F, Karkhaneh-Yousefi MA, et al. Simvastatin as an adjunctive therapy to risperidone in treatment of autism: a randomized, double-blind, placebo-controlled clinical trial. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):82–89.
   PubMed Web of Science ®Google Scholar
• King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):658–665.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Alikhani R, Kazemi MR, et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. J Child Adolesc Psychopharmacol. 2016 Nov;26(9):784–791.
   PubMed Web of Science ®Google Scholar
• Lenhard W, Lenhard A. Computation of effect sizes. Psychometrica. 2022. https://www.psychometrica.de/effect_size.html
   Google Scholar
• Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007 Nov 28;574(2–3):103–111. doi: 10.1016/j.ejphar.2007.07.031
   PubMed Web of Science ®Google Scholar
• Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology. 2007 Feb;190(3):373–382.
   PubMed Web of Science ®Google Scholar
• D’Alò GL, De Crescenzo F, Amato L, et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health Qual Life Outcomes. 2021 Jan 25;19(1):33. doi: 10.1186/s12955-021-01669-0
   PubMed Web of Science ®Google Scholar
• Bartram LA, Lozano J, Coury DL. Aripiprazole for treating irritability associated with autism spectrum disorders. Expert Opin Pharmacother. 2019 Aug 13;20(12):1421–1427.
   PubMed Web of Science ®Google Scholar
• Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013 Jun;15(3):217–233. doi: 10.1007/s40272-013-0024-6
   PubMed Web of Science ®Google Scholar
• Rizzo R, Pavone P. Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. Expert Rev Neurotherapeutics. 2016 Aug 02;16(8):867–874.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Maeda K, Yamada S, et al.et al The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole. In: Riederer P, Laux G Nagatsu Teditors. NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2020. p. 1–45.
   Google Scholar
• Mandic-Maravic V, Grujicic R, Milutinovic L, et al. Dopamine in autism spectrum disorders—focus on D2/D3 partial agonists and their possible use in treatment [review]. Front Psychiatry. 2022 Feb 03;12:12.
   Google Scholar
• Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012 (5):CD009043. doi: 10.1002/14651858.CD009043.pub2
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Yamamura K, Takayama T, et al. Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance. BMC Psychiatry. 2021 Apr 22;21(1):204. doi: 10.1186/s12888-021-03201-6
   PubMed Web of Science ®Google Scholar
• Noda S, Murakami A, Kimura S, et al. Duchenne muscular dystrophy successfully treated with aripiprazole in a patient with autism spectrum disorder symptoms including irritability. Intern Med. 2021 Dec 15;60(24):3983–3986. doi: 10.2169/internalmedicine.7248-21
   PubMed Web of Science ®Google Scholar
• Fallah MS, Shaikh MR, Neupane B, et al. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019 Apr;29(3):168–180.
   PubMed Web of Science ®Google Scholar
• Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22–30.
   PubMed Web of Science ®Google Scholar
• Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007 May;22(5):574–579.
   PubMed Web of Science ®Google Scholar
• Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1362–1374. doi: 10.1016/j.pnpbp.2008.01.008
   PubMed Web of Science ®Google Scholar
• Wei H, Dobkin C, Sheikh AM, et al. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PloS One. 2012;7(5):e36981. doi: 10.1371/journal.pone.0036981
   PubMed Web of Science ®Google Scholar
• Kumar H, Sharma B. Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. Brain Res Bull. 2016 Jun;124:27–39. doi: 10.1016/j.brainresbull.2016.03.013
   PubMed Web of Science ®Google Scholar
• Elnaiem W, Benmelouka AY, Elgendy AMN, et al. Evaluation of memantine’s efficacy and safety in the treatment of children with autism spectrum disorder: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2022;37(5):e2841. doi: 10.1002/hup.2841
   PubMed Web of Science ®Google Scholar
• Brignell A, Marraffa C, Williams K, et al. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):Cd013845. doi: 10.1002/14651858.CD013845.pub2
   PubMedGoogle Scholar
• Soorya LV, Fogg L, Ocampo E, et al. Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):475–484.
   PubMed Web of Science ®Google Scholar
• Alaghband-Rad J, Nikvarz N, Tehrani-Doost M, et al. Memantine-induced speech problems in two patients with autistic disorder. DARU, J Pharm Sci. 2013 Jul 2;21(1):54. doi: 10.1186/2008-2231-21-54
   Google Scholar
• Vanduchova A, Anzenbacher P, Anzenbacherova E. Isothiocyanate from broccoli, sulforaphane, and its properties. J Med Food. 2019 Feb;22(2):121–126. doi: 10.1089/jmf.2018.0024
   PubMed Web of Science ®Google Scholar
• Briones-Herrera A, Eugenio-Pérez D, Reyes-Ocampo JG, et al. New highlights on the health-improving effects of sulforaphane. Food Funct. 2018 May 23;9(5):2589–2606. doi: 10.1039/C8FO00018B
   PubMed Web of Science ®Google Scholar
• Marchezan J, Winkler dos Santos Eduardo Geyer A, Deckmann I, et al. Immunological dysfunction in autism spectrum disorder: a potential target for therapy. Neuroimmunomodulation. 2018;25(5–6):300–319. doi: 10.1159/000492225
   PubMed Web of Science ®Google Scholar
• Arteaga-Henríquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: a narrative review of randomized, placebo-controlled trials. CNS Drugs. 2023 Mar;37(3):215–229. doi: 10.1007/s40263-023-00993-x
   PubMed Web of Science ®Google Scholar
• Gogou M, Kolios G. The effect of dietary supplements on clinical aspects of autism spectrum disorder: a systematic review of the literature. Brain Dev. 2017 Sep;39(8):656–664. doi: 10.1016/j.braindev.2017.03.029
   PubMed Web of Science ®Google Scholar
• Lee TM, Lee KM, Lee CY, et al. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Aust N Z J Psychiatry. 2021 Feb;55(2):196–206.
   PubMed Web of Science ®Google Scholar
• Sun C-K, Cheng Y-S, Hung K-C. N-acetylcysteine is effective as add-on therapy to risperidone-based combination for children with autistic disorders. Aust N Z J Psychiatry. 2022;56(1):91–92. doi: 10.1177/00048674211041932
   PubMed Web of Science ®Google Scholar
• Pesko MJ, Burbige EM, Sannar EM, et al. The use of N-acetylcysteine supplementation to decrease irritability in four youths with autism spectrum disorders. J Pediatr Pharmacol Ther. 2020;25(2):149–154. doi: 10.5863/1551-6776-25.2.149
   PubMedGoogle Scholar
• Ure A, Cox GR, Haslam R, et al. Acetylcholinesterase inhibitors for autistic spectrum disorders. Cochrane Database Syst Rev. 2023 Jun 1;6(6):Cd013851. doi: 10.1002/14651858.CD013851.pub2
   PubMedGoogle Scholar
• Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002 Dec 14;325(7377):1422. doi: 10.1136/bmj.325.7377.1422/a
   PubMedGoogle Scholar
• Hertzman M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med. 2003;33(4):395–398. doi: 10.2190/JE5Q-1NFT-FL40-7PMW
   PubMed Web of Science ®Google Scholar
• Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):621–629. doi: 10.1089/cap.2006.16.621
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Melck D, Bisogno T, et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998 Dec;21(12):521–8.
   PubMed Web of Science ®Google Scholar
• Kerr DM, Downey L, Conboy M, et al. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res. 2013 Jul 15;249:124–32. doi: 10.1016/j.bbr.2013.04.043
   PubMed Web of Science ®Google Scholar
• Bertolino B, Crupi R, Impellizzeri D, et al. Beneficial effects of Co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism. CNS Neurosci Ther. 2017 Jan;23(1):87–98.
   PubMed Web of Science ®Google Scholar
• Hawkins ES, Ribeiro HA. Pentoxifylline review. J Am Podiatr Med Assoc. 1987 Dec;77(12):645–647. doi: 10.7547/87507315-77-12-645
   PubMed Web of Science ®Google Scholar
• Gupta S. Immunological treatments for autism. J Autism Dev Disord. 2000 Oct;30(5):475–479. doi: 10.1023/A:1005568027292
   PubMed Web of Science ®Google Scholar
• van der Most PJ, Dolga AM, Nijholt IM, et al. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009 May;88(1):64–75.
   PubMed Web of Science ®Google Scholar
• Ling Q, Tejada-Simon MV. Statins and the brain: new perspective for old drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Apr 3;66:80–86. doi: 10.1016/j.pnpbp.2015.11.013
   PubMed Web of Science ®Google Scholar
• Sierra S, Ramos MC, Molina P, et al. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23(2):307–318. doi: 10.3233/JAD-2010-101179
   PubMed Web of Science ®Google Scholar
• Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005 Mar 30;25(13):3312–3322. doi: 10.1523/JNEUROSCI.4262-04.2005
   PubMed Web of Science ®Google Scholar
• Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012 Apr 3;78(14):1096–1099. doi: 10.1212/WNL.0b013e31824e8f0d
   PubMed Web of Science ®Google Scholar
• Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology. 2011 Sep;61(4):574–582.
   PubMed Web of Science ®Google Scholar
• Panizzutti B, Skvarc D, Lin S, et al. Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis. Int J Mol Sci. 2023 Mar 9;24(6):5250. doi: 10.3390/ijms24065250
   PubMed Web of Science ®Google Scholar
• Luo Y, Lv K, Du Z, et al. Minocycline improves autism-related behaviors by modulating microglia polarization in a mouse model of autism. Int Immunopharmacol. 2023 Sep;122:110594.
   PubMed Web of Science ®Google Scholar
• Pardo CA, Buckley A, Thurm A, et al. A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord. 2013;5(1):9. doi: 10.1186/1866-1955-5-9
   PubMedGoogle Scholar
• Malek M, Ashraf-Ganjouei A, Moradi K, et al. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clin Neuropharmacol. 2020 Mar;43(2):39–45.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Mohammadi E, Mohammadi MR, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs. 2013 Dec;15(6):505–514.
   PubMed Web of Science ®Google Scholar
• Behmanesh H, Moghaddam HS, Mohammadi MR, et al. Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol. 2019 Nov;42(6):189–196.
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Rasa SM, Nikoo M, et al. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Res. 2015 Sep 30;229(1–2):181–187. doi: 10.1016/j.psychres.2015.07.043
   PubMed Web of Science ®Google Scholar
• Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1269–1272. doi: 10.1016/j.pnpbp.2010.07.005
   PubMed Web of Science ®Google Scholar
• Jaselskis CA, Cook EH Jr., Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992 Oct;12(5):322–327.
   PubMed Web of Science ®Google Scholar
• Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995 Jun;25(3):283–294.
   PubMed Web of Science ®Google Scholar
• Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000 Jun;30(3):245–255. doi: 10.1023/A:1005548619694
   PubMed Web of Science ®Google Scholar
• Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2011 Apr;168(4):395–399.
   PubMed Web of Science ®Google Scholar
• Lewis AS, van Schalkwyk GI, Lopez MO, et al. An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. J Autism Dev Disord. 2018 Aug;48(8):2748–2757.
   PubMed Web of Science ®Google Scholar
• Lewis AS, van Schalkwyk GI, Lopez MO, et al. An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. J Autism Dev Disord. 2018 Aug 1;48(8):2748–2757. doi: 10.1007/s10803-018-3536-7
   PubMed Web of Science ®Google Scholar
• VanPatten S, Al-Abed Y. The challenges of modulating the ‘rest and digest’ system: acetylcholine receptors as drug targets. Drug Discovery Today. 2017 Jan 1;22(1):97–104.
   PubMed Web of Science ®Google Scholar
• Kamerman PR, Vollert J. Greater baseline pain inclusion criteria in clinical trials increase regression to the mean effect: a modelling study. Pain. 2022;163(6):e748–e758. doi: 10.1097/j.pain.0000000000002468
   PubMed Web of Science ®Google Scholar
• Hengartner MP, Plöderl M. Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: effect size and method bias matter! Front Psychiatry. 2018;9:517. doi: 10.3389/fpsyt.2018.00517
   PubMed Web of Science ®Google Scholar